News
4d
Pharmaceutical Technology on MSNGilead wins positive European approval opinion for twice-yearly HIV injection
"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van ...
With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead Sciences, Hookipa Pharma has ...
Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...
Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...
Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...
Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting to a years-long kickback scheme to promote its panel of HIV medications.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Several of the events took place at ‘upscale restaurants’ in San Francisco, at costs of up to $163 per person, according to ...
Washington has long failed to come up with a solution for rising drug prices that addresses the concerns of drugmakers, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results